EQUIPMENT BUYING GUIDE · OWNER EXPERIENCE

EmpowerRF Review: Machine Costs, ROI and Practice Fit

InMode EmpowerRF workstation with its touchscreen and wheeled console
EmpowerRF workstation. Image: InMode. Attachments depend on the purchased configuration.

EmpowerRF combines aesthetic treatments such as Morpheus8 with technologies used in women’s intimate-health care. We owned a broadly configured system, and the biggest difference between its services was demand: Morpheus8 developed a more dependable business, while intimate-health bookings fluctuated sharply.

This EmpowerRF review helps med spa owners and OB/GYN practices compare machine costs, applicators, clinical evidence and return on investment (ROI). It combines our operating experience with the questions to resolve before buying a new or used system.

Darryl H.Sources checked November 6, 2026Practice-owner buying guidance

9+ years of med spa industry experience, including 7+ years co-owning and managing a practice. No current referral, commission or other commercial relationship with InMode. Clinical review pending. Disclosures.

Read the ownership experience ⁠↓ Compare the complete cost ⁠↓

THE OWNER’S ANSWER

In our practice, Morpheus8 built the more dependable business. EmpowerRF’s intimate-health options expanded what we could offer, but demand varied sharply, including months with no sales. The treatment range and responsive support were valuable; every attachment still needed its own patient pathway.

Buy the configuration your team can support and your patients have reason to choose. Build separate forecasts for aesthetic and intimate-health services, then test whether the established service can carry the commitment while the newer one develops.

Is EmpowerRF right for your med spa or OB/GYN practice?

The strongest fit is an adequately staffed practice that can explain why it needs this combination of technologies. An existing patient base is a useful starting point. It still needs to become assessed clinical need, interest in the proposed care and a workable appointment schedule.

For a med spa

Morpheus8 may be the familiar service that draws inquiries. Adding intimate-health services calls for suitable clinical expertise, private consultations, appropriate referral pathways and a distinct education plan.

Check: can the women’s health service stand on its own operationally, or is it just an optimistic addition to the purchase justification?

For an OB/GYN practice

Established relationships can make sensitive concerns easier to discuss. The business still needs room time, trained staff, clear financial conversations and a plan for follow-up. Cash-pay interest should be tested alongside existing care.

Check: which patients have a relevant, appropriately assessed need, and how does the proposed service compare with the options already available?

Pause if the forecast needs every attachment to be busy immediately. A smaller purchase, a staged expansion or a referral arrangement may fit the current practice better.

What treatments and applicators does EmpowerRF include?

InMode lists VTone, FormaV, Morpheus8/Morpheus8V, Morpheus8 Body and Tone on the EmpowerRF platform. A listing describes the platform’s available technologies; your signed configuration establishes what you are buying. InMode’s current platform page.

Read the configuration by the work each attachment would do
TechnologyWhat to understandWhat to price and verify
VToneIntravaginal electrical stimulation for pelvic-floor muscle rehabilitation; distinct from RF.Adapter, compatible single-use applicators, assessment and supervised appointment workflow.
FormaVBipolar RF heating. Its marketing name alone does not establish a US cleared indication.Exact handpiece, permitted use/reprocessing of patient-contact components, consumables and applicable labeling.
Morpheus8 face and BodyFractional RF microneedling. Applicator and tip generation matter.Face/body capability, compatible tips, numbing, comfort measures and room occupancy.
Morpheus8VA distinct intravaginal application described in published research.Exact applicator/tip, current US labeling, training, patient selection and follow-up requirements.
ToneExternal electrical muscle stimulation. This is separate from VTone.Included applicators, placement/setup time, intended services and demand.

Technology descriptions: InMode. Single-use VTone description: FDA K200293. Operational questions are our purchasing checklist, not treatment instructions. Obtain the current instructions for the exact components offered.

What was owning EmpowerRF actually like?

We bought our system around 2021, as I recall, with Morpheus8 face, Morpheus8 Body, VTone, FormaV, Morpheus8V and the Tone add-on. It gave us a broad menu. It also taught me why a broad menu and a dependable business are different things.

The numbers need the operating story beside them.

At our peak, Morpheus8 generated approximately $40,000 in monthly treatment revenue. We were selling roughly four to five packages a week during strong periods.

Intimate-health revenue was much less consistent. Once that service developed, some months were around $10,000, with stronger months around $15,000–$20,000. We also had months with no sales in that category.

These are my approximate historical recollections, not audited monthly accounts, profit figures or a forecast for another practice. Do not add the peaks together or annualize them as a typical year.

Morpheus8 had a clearer acquisition channel.

Google Ads helped bring interested patients to us. Advanced training and consistent before-and-after documentation helped us explain our approach. In consultations, we built a plan around the patient’s goal rather than treating every inquiry as a request for a single discounted session.

Intimate-health demand needed more deliberate development.

Search visibility and word of mouth helped, but we did not establish a consistently successful standalone marketing channel. Private conversations mattered. Our intake forms included an optional way to express interest in service categories, and patients sometimes first asked about intimate-health options after seeing them there.

VTone became an important part of that service. FormaV was frequently incorporated into assessed plans. Morpheus8V was used less than its potential place in the menu suggested because we had not built enough marketing and dedicated delivery capacity around it.

What I would carry forward

The treatment range and responsive support were valuable in our practice. Today I would still build the purchase around the services we could staff and market reliably, then test the quieter categories separately. I would also assign an owner to each service’s education, consultations and follow-up before assuming that an attachment would earn its place.

Is EmpowerRF FDA cleared, and what does the evidence show?

Clearance is specific to the applicator and intended use. VTone’s clearance includes pelvic-floor electrical stimulation for stress, urge and mixed urinary incontinence. The Morpheus8 record reviewed covers dermatologic uses; it does not name Morpheus8V. Ask for the current US labeling of every attachment you intend to use. VTone clearance; Morpheus8 clearance.

Small studies report improvements with intimate-health RF, but they do not settle which treatment works best. For genitourinary syndrome of menopause (GSM), the 2025 AUA/SUFU/AUGS guideline says evidence does not support RF or the named laser therapies for the outcomes assessed. That is a different question from VTone’s electrical-stimulation indication. Clinical leadership should review established alternatives before approving a service or its advertising. Guideline, statement 17.

RF microneedling needs a clinical safety plan.

The FDA’s October 2025 communication describes reports of burns, scarring, unwanted fat loss, disfigurement and nerve damage with certain RF microneedling uses. It is a category safety communication, not an EmpowerRF complication rate. Budget for trained delivery, appropriate patient selection, consent, aftercare and escalation. FDA safety communication.

See the clearance records and clinical study details
The distinctions that matter before building your menu
Record or evidenceWhat it supportsWhat it does not establish
VTone: K200293Electrical stimulation and neuromuscular re-education of weak pelvic-floor muscles for stress, urge and mixed urinary incontinence in women.A guarantee of improvement, or clearance for every vaginal symptom.
Morpheus8: K231790Dermatologic soft-tissue coagulation/contraction or hemostasis; the record includes an energy-dependent skin-type restriction.A general vaginal, sexual-function or urinary indication. The record reviewed does not name Morpheus8V.
Forma-family record: K210492Named Forma-family applicators have indications including temporary relief of minor muscle pain/spasm and improved local circulation.That the FormaV name or a proposed intimate-health use is covered. Ask for the exact mapping in writing.
Tone: K192249Listed muscle-stimulation and pain-related uses, including muscle re-education.VTone’s urinary indication transferring to the external Tone attachment.

In July 2018, the FDA asked InMode about the regulatory basis for FormaV and FractoraV marketing for certain women’s health uses. This is historical context; obtain current labeling for the proposed service. FDA’s dated letter.

What the studies add

A 2023 prospective study treated 20 women with Morpheus8V and reported improvements through six months in women with stress or mixed incontinence alongside genitourinary syndrome of menopause (GSM). It compared outcomes with baseline; the abstract describes no randomized control group. Study abstract.

A 2021 retrospective study compared bipolar and monopolar RF in 101 patients. Symptoms improved, but some women had also received CO2 treatment, outcomes were subjective and improvement weakened between three and six months. The authors called for prospective randomized research. Full study.

Research continues to develop. A 2026 randomized trial of 62 women found improvements in sexual-function and vaginal-health scores compared with sham treatment, with follow-up 12 weeks after treatment. It used an INDIBA monopolar system, not EmpowerRF. Those findings belong in the wider evidence discussion but cannot establish that FormaV or Morpheus8V produces the same results. 2026 trial.

How much does an EmpowerRF machine cost?

A new EmpowerRF machine requires an itemized quote; we have not verified a current public US price. Get an itemized quote. A used console, a partially equipped system and a new package with training and support are not equivalent purchases.

For a concrete secondary-market example, MRP listed a pre-owned 2022 EmpowerRF system for $22,995 when checked November 6, 2026. Its inclusion list named a Morpheus8 applicator, a VTone adapter and Tone components. It did not list the complete configuration I describe owning. This is one seller’s asking price, not a completed sale, new-system estimate or market average. Dated listing and inclusions.

Before buying used, establish whether the manufacturer will support the serial number, what transfer or inspection process applies, which consumables you can obtain, and whether training and warranty are available. Get those answers before paying a deposit.

Put the complete commitment on one page.

  • Acquisition: console, attachments, starting supplies, shipping, tax and any required setup.
  • Financing: cash price, amount financed, payment schedule, fees, total scheduled payments, end-of-term obligations and written early-payoff examples.
  • Delivery: staff time, room occupancy, tips and patient-contact components, numbing, cleaning and appropriate comfort measures.
  • Continuity: service coverage, replacement supplies, retraining, repairs and a plan for downtime.
  • Demand: education, consultations, advertising, follow-up and the cash reserve needed during a slower launch.

Our recurring supplies included Morpheus8 tips, VTone probes, components for the intimate-health handpieces, numbing and, where used, Pro-Nox breathing disposables and gases. Marketing was another meaningful variable. Get current per-treatment supply costs for your own configuration.

Do not judge financing by the monthly payment alone. Ask the lender for the total paid if you follow the schedule and the payoff amount at specific earlier dates. Early settlement savings depend on the contract; do not assume that every equipment agreement works like an ordinary amortizing loan.

InMode’s published US terms describe sales as final and non-refundable. Read the terms that accompany your own quote and get negotiated training, warranty and service commitments into the agreement. InMode’s US purchase terms.

EmpowerRF ROI: how many treatments cover monthly costs?

Divide the monthly commitment by what each completed visit contributes after its direct costs. Use the price actually earned per visit after package discounts, then subtract supplies, direct provider pay and card-processing or patient-financing fees. A package sale is not the same as a completed appointment.

Build the calculation from your quote.

  1. Contribution per visit: allocated treatment revenue − visit-dependent costs.
  2. Monthly commitment: equipment payment + additional fixed staffing, marketing, service and other costs needed to run the service.
  3. Visits needed for monthly cash coverage: monthly commitment ÷ positive contribution per visit, rounded up.

Count each expense once. If provider pay is already deducted per visit, do not add that same pay again as fixed staffing.

For a mixed menu, calculate contribution separately for Morpheus8, VTone and the other services. Multiply each by its expected completed visits, then add the contributions and compare the total with the monthly commitment.

Calculate my equipment costs and ROI ⁠→

The slow-month test matters more than the peak.

Run the plan with no new intimate-health bookings. Can realistic Morpheus8 activity cover the commitment, or does the practice need a reserve? We experienced months with no intimate-health sales, which is why I would test that case before treating an additional attachment as dependable revenue.

Next, use the capacity planner to check whether staff, rooms and the shared console can deliver the required visits, including preparation and room reset. Available appointment time is not proof that those appointments will fill.

This calculates monthly cash coverage, not full investment payback or practice profit. Model the deposit, launch costs, future cash flows and financing separately for a return-on-investment decision. Track package cash collected alongside the remaining visits you still owe patients.

How do you turn the purchase into appropriate bookings?

Make it easy to ask a private question, understand a recommendation and follow a manageable plan. Our best operational lessons were about the patient’s decision, not another list of machine features.

Start with the consultation.

We used a thorough intake questionnaire so the provider could discuss the patient’s concerns privately and recommend a plan. An optional service-interest checklist on the general intake form also introduced treatments patients had not known were available. Interest opened a conversation; it did not determine candidacy.

For an intimate-health service, give reception staff a discreet way to offer the right consultation without asking patients to explain symptoms in public. Make the pathway clear on the website. Keep diagnosis and treatment decisions with the appropriately qualified clinical team.

Make the package manageable without disguising its price.

We offered third-party financing and also used staged payments tied to visits. For example, a service priced at $1,000 per visit or $2,500 for three could be paid as follows:

Visit 1: $1,000 · Visit 2: $1,000 · Visit 3: $500

Three visits, $2,500 total. The final installment completes the package price.

Total: $2,500. This reproduces the payment structure I described, not a current EmpowerRF treatment quote. It reduced the initial package outlay while retaining the full planned package price. Written terms should explain cancellation, changes in clinical suitability and unused treatment obligations.

Sell the treatment plan, not just the machine.

When your advertising credits “Morpheus8” with the entire result, you teach patients to compare your practice by the price of Morpheus8. The machine name helps people find the service. Your consultation, website and follow-up need to explain what your team adds: assessment, training, treatment selection and a plan for the patient’s goal.

That was the approach we used. Google Ads brought inquiries; advanced training, documented before-and-after results and a clear consultation helped explain why someone should choose us. Sometimes an appropriate complementary service or take-home skincare added value to the plan instead of another price cut. A take-home product also gave the patient something tangible to use between appointments.

A named plan is useful when it describes a real difference in care. Show the goal, what is included, who provides it, the total price and how progress will be reviewed. Consistent before-and-after documentation makes that expertise visible; individual results still vary.

Cost every included service and product. Staff time, room capacity and supplies are real costs, even when an add-on is advertised as complimentary. The clinical team decides which combinations and timing are appropriate.

Our “treat to complete” approach meant planning toward the assessed goal and discussing maintenance from the start. Use service pricing that includes delivery costs and maintenance plans with clear benefits to explain the longer-term commitment, rather than leaving patients with a one-off package and no next step.

For the operational steps between an inquiry and an attended consultation, use our med spa booking and follow-up guide. It covers response coverage, price conversations and appointment preparation.

EmpowerRF vs Morpheus8, Optimas MAX and EMSELLA

Compare the clinical and business job you need done. One “EmpowerRF versus…” winner would hide the fact that pelvic-floor stimulation, RF microneedling and a broader aesthetic menu solve different purchasing questions.

  • If most demand is aesthetic RF microneedling: compare the exact Morpheus8 configuration with dedicated RF systems. Our RF microneedling equipment guide and Morpheus8 MAX guide help distinguish technologies and generations.
  • If the practice needs IPL and hair removal too: compare the complete menu and ownership costs of Optimas MAX. Shared branding does not make its attachments an EmpowerRF configuration.
  • If the main need is pelvic-floor or menopause care: have clinical leadership compare established care, referral options and any proposed device on the specific diagnosis and evidence. A familiar device name is not a substitute for that review.
  • If the service has not been validated: compare a staged launch or referral pathway with buying the whole configuration immediately.

If pelvic-floor stimulation is the main purchase, compare the patient workflow with BTL EMSELLA, an external electromagnetic system used with patients clothed, rather than an intravaginal electrical-stimulation applicator. That difference can matter to patient preference and room workflow; it does not establish clinical superiority. Ask for comparable evidence and complete costs.

For a busy practice, consider whether a shared console will constrain simultaneous services. A larger number of available attachments does not increase the number of consoles available at the same time.

What should be answered before you sign?

  1. Configuration: which console generation, applicators, tips and starting supplies are included by part number?
  2. Clinical use: what current US labeling and evidence support each service you plan to offer?
  3. Training: who trains the initial team, signs off competence and supports replacement staff?
  4. Supplies: what is single use, what needs reprocessing, and what are current prices, minimum orders and delivery times?
  5. Support: what happens if the console or a handpiece fails, and who pays for transport, repair and downtime?
  6. Finance: what are the total payments and the early-payoff amounts, not just the monthly installment?
  7. Demand: who owns each service’s education, consultations, bookings and follow-up?
  8. Decision: what finding would make you buy a smaller configuration, wait or choose another route?

MAKE THE QUOTE COMPARABLE

See what the monthly payment leaves out.

Put the equipment, financing, training and recurring costs beside each other. Identify missing information before choosing a package.

Compare my equipment quotes ⁠→

Use the tool without an account. A free workspace supports saving plans. Self-service planning; no automatic sharing with vendors.

Preview of the NuWays MD equipment quote comparison tool
Free equipment quote comparison tool

EmpowerRF buying questions

EmpowerRF vs Morpheus8: what is the difference?

No. EmpowerRF is a workstation with a range of available technologies. Morpheus8 is one treatment family that can be included. Confirm the exact handpieces, tips and generation; do not assume every Morpheus8 feature is available on every platform.

Does EmpowerRF include all the attachments?

The platform page lists available technologies. Your itemized quote and purchase agreement establish what is supplied. A used listing may include only a few attachments even when it carries the same workstation name.

Is EmpowerRF worth it for a med spa?

It can generate meaningful treatment revenue, as our experience illustrates. Profit depends on demand, delivery costs, financing, staffing and overhead. Use conservative completed-treatment counts and test slow months rather than assuming another practice’s peak revenue is repeatable.

Is EmpowerRF a better fit for an OB/GYN than a med spa?

Neither specialty automatically wins. An OB/GYN practice may already have trusted relationships around relevant concerns; a med spa may have stronger aesthetic demand. The best fit depends on clinical capabilities, patient needs, cash-pay interest and the services the team can consistently support.

Can I use the same forecast for VTone and Morpheus8?

No. Their visit costs, timing, patient journey and demand may differ. Build each service separately, then combine their contribution and scheduling needs into the overall equipment plan.

Should I buy a used EmpowerRF system?

Only after checking its exact configuration, condition, support eligibility, supply access, training and total cost to put it into service. A lower asking price is useful information, but it is not a complete ownership quote.

Sources and editorial method

Sources checked November 6, 2026. Darryl H.’s ownership account is a historical recollection, recorded in an interview for this guide. Purchase pricing is not disclosed. Historical revenue is not audited profit or an earnings forecast. No current commercial relationship with InMode exists. Clinical review is pending; this is a buying guide, not a treatment protocol.

Manufacturer material establishes listed technologies, not independent proof of effectiveness. FDA records are mapped to the names and uses they actually identify. The clinical summaries below do not turn small observational studies into universal success rates.

View the sources and what they support

How we review evidence · Disclosures

Useful next reads